Document Detail


Use of liver function tests as predictors of rifampicin metabolism in cirrhosis.
MedLine Citation:
PMID:  7267969     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Normal subjects taking rifampicin regularly, show a fall in serum and urinary drug concentrations from enzyme induction and increased biliary excretion. In cirrhosis, hepatocellular dysfunction and impaired biliary excretion may prevent these changes, but there is little information on how the drug should be prescribed in such patients. Serum and urinary rifampicin concentrations were therefore measured in thirteen patients and five controls during a seven-day course (600 mg/day). In controls, peak serum concentrations on Day 7 were lower than on Day 1 (7.0 +/- 3.0 and 8.0 +/- 1.0 microgram/ml respectively) and this was also the case for nine cirrhotic patients with mild impairment of liver function (6.0 +/- 1.0 and 11.0 +/- 2.0 microgram/ml (p less than 0.02). In both groups there was an accompanying fall in urinary rifampicin excretion due to a decrease in desacetylrifampicin excretion. In the remaining four cirrhotic patients, peak serum rifampicin levels rose from 11.0 +/- 5.0 to 17.0 +/- 6.0 microgram/ml and urinary excretion of desacetylrifampicin did not fall. Although values for serum albumin and prothrombin time were of limited value in predicting drug accumulation, pretreatment levels of bilirubin exceeding 50 mumol/l were present in all four patients showing an increase in serum rifampicin concentration. Furthermore, only in this group was there a rise in serum bilirubin during treatment, almost certainly the result of competition between rifampicin and bilirubin for hepatic uptake and excretion. In all patients with cirrhosis, bilirubin concentrations exceeding 50 mumol/l should be an indication for reduction of rifampicin dosage.
Authors:
J B McConnell; P R Powell-Jackson; M Davis; R Williams
Related Documents :
10048549 - Reliability of taurine concentrations measured in single urine samples obtained from do...
8456539 - Oxalate status in stone-formers. two distinct hyperoxaluric entities.
19896169 - Exposure assessment of pm2.5 and urinary 8-ohdg for diesel exhaust emission inspector.
2161409 - Increased leukotriene e4 excretion during antigen-induced bronchoconstriction in allerg...
3748249 - Silicon metabolism. ii. renal handling in chronic renal failure patients.
11382549 - Blood plasma response and urinary excretion of nitrite and nitrate in milk-fed calves a...
15174309 - Age dependence of the levels of plasma norepinephrine, aldosterone, renin activity and ...
17492949 - The influence of the route of oestrogen administration on serum levels of cortisol-bind...
22399739 - Reduced o2 concentration during cam development--its effect on physiological parameters...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Quarterly journal of medicine     Volume:  50     ISSN:  0033-5622     ISO Abbreviation:  Q. J. Med.     Publication Date:  1981  
Date Detail:
Created Date:  1981-10-25     Completed Date:  1981-10-25     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0401027     Medline TA:  Q J Med     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  77-82     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Drug Administration Schedule
Humans
Liver Cirrhosis / metabolism*,  physiopathology
Liver Function Tests*
Rifampin / administration & dosage,  metabolism*
Chemical
Reg. No./Substance:
13292-46-1/Rifampin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chronic bronchial suppuration and inflammatory bowel disease.
Next Document:  The timing of histological damage following a single challenge with gluten in treated coeliac diseas...